Chromosome 20q deletion: A recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission

American Journal of Clinical Pathology

Volumn 135, Issue 3, 2011, Pages 391-397

  Sun, Jianlan ^a   Yin, C Cameron ^a   Cui, Wei ^a   Chen, Su S ^a   Medeiros, L Jeffrey ^a   Lu, Gary ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelogenous leukemia; Deletion 20q; Recurrent cytogenetic abnormality

Indexed keywords

BCR ABL PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CHROMOSOME 20Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DISEASE SEVERITY; FEMALE; HEMATOLOGY; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; MORPHOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE COUNT; BONE MARROW; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE TRANSLOCATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; REMISSION;

ADULT; AGED; BIOPSY, NEEDLE; BONE MARROW; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 20; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REMISSION INDUCTION; TRANSLOCATION, GENETIC;

EID: 79954432996     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQFSC9ZJNMAZ6     Document Type: Article

References (21)

1. Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Oudat R, Khan Z, Glassman AB. A unique, complex variant Philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia. Arch Pathol Lab Med. 2001;125:437-439. (Pubitemid 32207189)
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340. (Pubitemid 29196596)
4. Kantarjian HM, Jorge C, Paul la R, et al. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010;116:1419-1430.
5. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641. (Pubitemid 30004667)
6. Yin CC, Cortes J, Barkoh B, et al. t (3;21) (q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer. 2006;106:1730-1738.
7. Yin CC, Medeiros LJ, Glassman AB, et al. t (8;21) (q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol. 2004;121:836-842. (Pubitemid 38669277)
8. Yin CC, Abruzzo LV, Qiu X, et al. del (15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009;192:18-23.
9. Merzianu M, Medeiros LJ, Cortes J, et al. inv (16) (p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases. Am J Clin Pathol. 2005;124:807-814. (Pubitemid 41532516)
10. Morris CM, Honeybone LM, Hollings PE, et al. Localization of the SRC oncogene to chromosome band 20q11.2 and loss of this gene with deletion (20q) in two leukemic patients. Blood. 1989;74:1768-1773. (Pubitemid 19251558)
11. Reid AG, Swanton S, Grace C, et al. Double Philadelphia masquerading as chromosome 20q deletion: a new recurrent abnormality in chronic myeloid leukaemia blast crisis. Br J Haematol. 2003;123:442-448. (Pubitemid 37363484)
12. Bumm T, Muller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941-1949. (Pubitemid 36237597)
13. Schnittger S, Bacher U, Kern W, et al. RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia. Br J Haematol. 2009;146:665-668.
14. Hao S, Sanger W, Onciu M, et al. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:1266-1272. (Pubitemid 35462993)
15. Shaffer LG, Tommerup N, eds. ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Basel, Switzerland: Karger; 2005.
16. Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol. 2004;17:96-103. (Pubitemid 41656458)
17. Heim S, Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 3rd ed. New York, NY: Wiley-Liss; 2009.
18. Huh J, Tiu RV, Gondek LP, et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer. 2010;49:390-399.
19. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 2002;16:1390-1393.
20. Gong JG, Costanzo A, Yang HQ, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatininduced DNA damage. Nature. 1999;399:806-809. (Pubitemid 29293179)
21. Kharbanda S, Pandey P, Jin S, et al. Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997;386:732-735. (Pubitemid 27193496)